Tag: pharmaceutical

BRBR LOSS ALERT: BellRing Brands, Inc. Investors with Losses are Reminded of the Ongoing Securities Fraud Investigation – Contact BFA Law (NYSE:BRBR)

BellRing Brands, Inc. investors that lost money are notified to contact BFA Law about its ongoing securities fraud class action investigation.

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options

Hims & Hers (HIMS) Drops Amid Reported Details of FTC Investigation, Adding To Investor Scrutiny In Pending Securities Class Action – Hagens Berman

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- On August 14, 2025 the price of Hims & Hers Health (NYSE: HIMS) shares significantly dropped in after-hours trading after the financial press reported that the FTC is probing the company’s advertising practices and whether it makes it too difficult for customers to cancel subscriptions.

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025...

Cingulate Provides Management Team Update

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

Natural DHT Blockers Take Center Stage in Hair Loss Defense — HairSmart Leads the Charge with Award-Winning Formula

HairSmart’s award-winning natural DHT Blocker offers a safe, plant-based solution to combat hair loss, clinically proven, side-effect-free, and effective.

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

2H 2025 is shaping up to be a defining year for LIXTE (Nasdaq: LIXT) and its lead compound LB-100

HIMS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure...

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the “Class Period”), of the important August 25, 2025 lead plaintiff deadline.

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsPharmaceutical

Sportradar Group AG Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – SRAD

FLSmidth: Transactions under share buy-back programme

Enterome presents Phase 1/2 iNHL interim data at EHA demonstrating durable OncoMimics™-induced CD8 T cell responses and clinical activity

Tag: pharmaceutical

BRBR LOSS ALERT: BellRing Brands, Inc. Investors with Losses are Reminded of the Ongoing Securities Fraud Investigation – Contact BFA Law (NYSE:BRBR)

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Hims & Hers Health

Hims & Hers (HIMS) Drops Amid Reported Details of FTC Investigation, Adding To Investor Scrutiny In Pending Securities Class Action – Hagens Berman

Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR | MarketsandMarkets™

Cingulate Provides Management Team Update

Natural DHT Blockers Take Center Stage in Hair Loss Defense — HairSmart Leads the Charge with Award-Winning Formula

Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

HIMS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors with Losses in Excess of $100K to Secure...

COSCIENS Biopharma Inc. Reports Second Quarter 2025 Financial Results and Provides Strategic Initiatives Update

CleanSpace Continues Rapid Growth, Strengthening its Concept-to-Commercialization Model

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us